Schering-Plough reported higher fourth-quarter earnings in-line with Wall Street expectations.
The Kenilworth, N.J.-based company posted net income of $182 million, or 12 cents a share, up from $104 million, or seven cents a share, in the year-ago quarter. Earnings were led by strong sales of arthritis treatment Remicade.
Chief executive Fred Hassan told CNBC that the drug company's latest earnings are a further sign that a three-year-old restructuring is having a positive impact.
"We are going into this year with momentum, we are growing very nicely on the top line, we're exerting financial discipline, and our bottom line is growing faster than our top line," Hassan said in an appearance on "Power Lunch" on Monday. "That's a great strategy to have."